BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. by Quesseveur, G. et al.
BDNF overexpression in mouse hippocampal
astrocytes promotes local neurogenesis and elicits
anxiolytic-like activities
G Quesseveur1,11, DJ David1,11, MC Gaillard2,3, P Pla4,5,6,7, MV Wu8,9, HT Nguyen1, V Nicolas10, G Auregan2,3, I David1,
A Dranovsky8,9, P Hantraye2,3, R Hen8,9, AM Gardier1, N De´glon2,3,12 and BP Guiard1
The therapeutic activity of selective serotonin (5-HT) reuptake inhibitors (SSRIs) relies on long-term adaptation at pre- and post-
synaptic levels. The sustained administration of SSRIs increases the serotonergic neurotransmission in response to a functional
desensitization of the inhibitory 5-HT1A autoreceptor in the dorsal raphe. At nerve terminal such as the hippocampus, the
enhancement of 5-HT availability increases brain-derived neurotrophic factor (BDNF) synthesis and signaling, a major event in
the stimulation of adult neurogenesis. In physiological conditions, BDNF would be expressed at functionally relevant levels in
neurons. However, the recent observation that SSRIs upregulate BDNF mRNA in primary cultures of astrocytes strongly suggest
that the therapeutic activity of antidepressant drugs might result from an increase in BDNF synthesis in this cell type. In this
study, by overexpressing BDNF in astrocytes, we balanced the ratio between astrocytic and neuronal BDNF raising the
possibility that such manipulation could positively reverberate on anxiolytic-/antidepressant-like activities in transfected mice.
Our results indicate that BDNF overexpression in hippocampal astrocytes produced anxiolytic-/antidepressant-like activity in the
novelty suppressed feeding in relation with the stimulation of hippocampal neurogenesis whereas it did not potentiate the effects
of the SSRI fluoxetine on these parameters. Moreover, overexpressing BDNF revealed the anxiolytic-like activity of fluoxetine in
the elevated plus maze while attenuating 5-HT neurotransmission in response to a blunted downregulation of the 5-HT1A
autoreceptor. These results emphasize an original role of hippocampal astrocytes in the synthesis of BDNF, which can act
through neurogenesis-dependent and -independent mechanisms to regulate different facets of anxiolytic-like responses.
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Introduction
The therapeutic activity of selective serotonin (5-HT) reuptake
inhibitors (SSRIs) relies on long-term adaptation at pre- and
post-synaptic levels. At the post-synaptic level, compelling
evidence has demonstrated that the sustained, but not acute,
administration of SSRIs stimulates adult hippocampal neuro-
genesis, whereas the disruption of this phenomenon prevents
the behavioral effects of these antidepressants in mice.1
Although the complex biological and psychobiological
changes associated with depression and related treatments
cannot be attributed to neurogenesis alone,2 this particular
property of SSRIs has been reported in humans3 and in non-
human primates.4 We recently demonstrated that the disrup-
tion of adult hippocampal neurogenesis compromises the
anxiolytic-/antidepressant-like activity of the SSRI fluoxetine
in some, but not all, behavioral paradigms, thereby suggesting
the existence of both neurogenesis-dependent and neuro-
genesis-independent mechanisms of action.5 A number of
factors have been proposed to participate in SSRI-induced
adult hippocampal neurogenesis. Among the many long-term
targets of SSRI treatments, neurotrophins, particularly brain-
derived neurotrophic factor (BDNF), have been well studied.
BDNF is the most abundant neurotrophin in the brain and is
predominantly synthesized by neurons, where the normal
physiological levels are rapidly and potently regulated through
ongoing neuronal activity.6 Evidence demonstrates that
chronic SSRI treatments increase BDNF expression in the
dentate gyrus (DG) of the hippocampus,7 which in turn
promotes the in vivo proliferation and differentiation of
neuronal progenitor cells,8–11 accelerates the maturation of
newborn neurons and facilitates their survival.10–12 Taken
together, these data establish a relationship between anti-
depressant activity, BDNF synthesis and the stimulation of
hippocampal neurogenesis.
There is increasing evidence that SSRIs also activate glial
cells, particularly astrocytes.13 Consistent with this hypothesis,
1Laboratoire de Neuropharmacologie EA3544, Faculte´ de Pharmacie, Universite´ Paris-Sud, Chaˆtenay-Malabry Cedex, France; 2Commissariat a` l’Energie Atomique,
Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center, Fontenay-aux-Roses, France; 3CNRS, URA2210, Fontenay-aux-Roses, France;
4Institut Curie, Orsay, France; 5CNRS UMR 3306, Orsay, France; 6INSERM U1005, Orsay, France; 7Universite´ Paris Sud, Orsay, France; 8Department of Psychiatry and
Neuroscience, Columbia University, New York, NY, USA; 9New York State Psychiatric Institute, New York, NY, USA and 10Plateforme Imagerie Cellulaire, Faculte´ de
Pharmacie, Universite´ Paris Sud, Chaˆtenay-Malabry, France
Correspondence: Professor A Gardier, Laboratoire de Neuropharmacologie EA3544, Faculte´ de Pharmacie, Universite´ Paris XI, Chaˆtenay-Malabry, 92290 France.
E-mail: alain.gardier@u-psud.fr
11These authors contributed equally to this work.
12Present address: Laboratory of Cellular and Molecular Therapies, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland.
Received 7 March 2013; accepted 15 March 2013
Keywords: antidepressant; astrocytes; brain-derived neurotrophic factor; hippocampus; neurogenesis; selective serotonin reuptake inhibitors
Citation: Transl Psychiatry (2013) 3, e253; doi:10.1038/tp.2013.30
& 2013 Macmillan Publishers Limited All rights reserved 2158-3188/13
www.nature.com/tp
fluoxetine has been shown to reverse the stress-induced
reduction of hippocampal glial fibrillary acidic protein (GFAP)
expression in rats.14 Therefore, an increased activity or
density of astrocytes could represent a common cellular
mechanism underlying the effects of pharmacological15 and
non-pharmacological antidepressive strategies.16 In vitro
studies suggest that astrocytes express very low levels of
BDNF,17 and whether this neurotrophin would be recruited in
response to antidepressant treatment to modulate their
therapeutic activity remains unknown. The presence of SERT
(serotonin transporter) on astrocytes18,19 along with the
recent observation that fluoxetine upregulates BDNF in
primary astrocyte cultures20 support this hypothesis but has
never been examined in vivo.
In the present study by selectively overexpressing BDNF in
hippocampal astrocytes by the mean of an original and
efficient gene transfer strategy,21 we balanced the ratio
between neuronal vs astrocytic BDNF thereby modeling the
putative post-synaptic activity of SSRIs. We anticipated that
such manipulation either alone or in combination with the
sustained administration of fluoxetine could positively rever-
berate on the anxiolytic-/antidepressant-like behavior of
transfected mice. In addition, we tested the hypothesis that
changes in behavioral responses might result from the finely
tuned regulation of hippocampal neurogenesis and/or ser-
otonergic neurotransmission, which are twomajor elements in
the therapeutic activity of SSRIs. Depending on the paradigm,
the overexpression of BDNF in hippocampal astrocytes
elicited anxiolytic-/antidepressant-like effects either alone or
in combination with fluoxetine thereby providing the first
in vivo evidence that this cell type might be a key partner of
neurons during antidepressant treatment.
Materials and methods
Animals. Male SvEv129 mice (7- to 9-week-old), weighing
25–35 g (Taconic, Ejby, Denmark) were used in the present
study according to the protocol described in Supplementary
Figure S1. They were initially divided into two groups pre-
injected with lentiviral vector containing the green fluorescent
protein (GFP) (lenti-GFP control mice) or the BDNF
(lenti-BDNF mice). One month after stereotaxic injection of
lentivirus, lenti-GFP and lenti-BDNF mice were administered
the vehicle or fluoxetine for 4 weeks.
Stereotaxic injection of lentiviral vector. For the stereo-
taxic injections, mice were anesthetized with a mixture of
ketamine (75mg kg 1) and xylazine (10mg kg 1), adminis-
tered intraperitoneally (i.p.). Lentiviral vectors (see
Supplementary Materials and Methods) were injected using
34-gauge blunt-tip needle linked to a Hamilton syringe
(Hamilton, Reno, NV, USA) by a polyethylene catheter.
The viruses were diluted in PBS-1% BSA to reach a final
concentration of 100 ng p24ml 1. Mice received a total
volume of 1 ml at a rate of 0.2 ml min 1. The stereotaxic
coordinates for the bilateral injections in the hippocampus
were (in mm from bregma): anteroposterior (AP)  2.2,
lateral (L) ±2.0 and ventral (V)  2.0 (according to Paxinos
and Franklin22). At the end of the injection, the needle
was left in place for 5min before being slowly removed.
The labeling of the site of injection by GFP is depicted in
Figure 1e and Supplementary Figure S2A.
ELISA and western blots. BDNF levels in the hippocampus
and the striatum of lenti-GFP and lenti-BDNF were measured
by anti-BDNF sandwich-ELISA using BDNF Emax Immu-
noassay system (Promega, Charbonnie`res, France) accord-
ing to a protocol described previously. Additionally, western
blots were used to detect extracellular signal-regulated
kinase (ERK) and protein kinase B (Akt) phosphorylation
(see Supplementary Materials and Methods).
Behavioral testing. The originality of our protocol lies in the
fact that the same cohort of animal was tested in different
behavioral paradigms of anxiety and depression according to
a procedure described previously.5 Behavioral procedure
starts with the less stressful paradigm and finishes with the
most stressful one. So each animal, over 1 week, was
successively tested in the elevated plus maze (EPM), the
novelty suppressed feeding (NSF), the tail suspension test
(TST) and the splash test (ST) paradigm. A 2-day period
between each test was respected (Supplementary Figure
S1). Detail of these tests as well as x-irradiation procedure
can be retrieve in Supplementary Materials and Methods.
Immunohistochemistry
Ki67 labeling for proliferation study. We first looked at
proliferation using Ki-67 as a marker for cell division. Ki-67,
a nuclear protein expressed in all phases of the cell cycle
except for G0, can be used as an endogenous marker
alternative to bromodeoxyuridine (BrdU) incorporation.23
BrdU labeling for survival study. Mice were administered
with BrdU (150mg kg 1, i.p. dissolved in saline), twice a day
during 3 days before the start of the treatment. After
anesthesia with ketamine and xylazine (75mg kg 1 keta-
mine; 10mgkg 1 xylazine; i.p.), mice were perfused
transcardially (cold saline, followed by 4% cold paraformal-
dehyde at 4 1C). The identification of survival cells was
performed by BrdU labeling (see Supplementary Materials
and Methods).
Doublecortin labeling for maturation index and dendritic
morphology studies. The identification of survival cells
was performed by doublecortin (DCX) labeling (see
Supplementary Materials and Methods). Once performed,
DCXþ cells were subcategorized according to their dendritic
morphology: DCXþ cells with no tertiary dendritic processes
and DCXþ cells with complex, tertiary dendrites. The
maturation index was defined as the ratio of DCXþ cells
possessing tertiary dendrites over the total DCXþ cells.
Intracerebral electrophysiology. Mice were anesthetized
with chloral hydrate (400mgkg 1; i.p.) and placed in a
stereotaxic frame (using the David Kopf mouse adaptor) with
the skull positioned horizontally. Micropipettes were posi-
tioned on the lambda and lowered into the dorsal raphe (DR),
usually attained at a depth of between 2.5 and 3.5mm from
the brain surface.22 The presumed DR 5-HT neurons were
then identified accordingly using the following criteria: a slow
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(0.5–2.5Hz) and regular firing rate and a long duration,
positive action potential.24 Changes in the firing activity were
expressed as percentages of baseline firing rate.
Intracerebral microdialysis. Mice were anesthetized with
chloral hydrate (400mg kg 1; i.p.) and placed in a stereo-
taxic frame (using the David Kopf mouse adaptor) with the
skull positioned horizontally. Anesthetized mice were
implanted with probes located in the hippocampus and DR.
The stereotaxic coordinates for the hippocampus were (in
mm from bregma): AP  2.5, L±2.5, V  2.5 and for the DR
(in mm from lambda): AP 0, L 0, V  3.5 (according to
Paxinos and Franklin22). Active lengths of the microdialysis
probes in the hippocampus and DR were 1.5 and 1mm,
respectively. Microdialysis experiments were conducted
following a protocol previously described in our laboratory.25
These basal values were calculated for each mouse before
the challenge of fluoxetine or vehicle. Dialysate samples
were analyzed for 5-HT by high-performance liquid chroma-
tography method (limit of sensitivityE0.5 fmol per sample;
signal-to-noise ratio¼ 2). At the end of the experiments,
localization of microdialysis probes was verified
histologically.
8-Hydroxy-N,N-dipropyl-2-aminotetralin-induced
hypothermia. Body temperature was assessed intrarec-
tally, using a lubricated probe inserted B2 cm and a TH-5
Thermalert Monitoring Thermometer (Physitemp, Clifton, NJ,
USA). Mice were singly housed in clean cages for 10min,
and three baseline body temperature measurements were
taken. After the third baseline measurement, animals
received 8-Hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-
DPAT) (100 mg kg 1; subcutaneous (s.c.)) and body tem-
perature was monitored every 10min for a total of 60min.
Decreases in body temperatures were represented as a
change from the mean baseline measurement.
Drugs and administration. Fluoxetine (18mgkg 1 per
day) was purchased from ANAWA (Wangen, Switzerland)
and administered in the drinking water in opaque bottles. For
electrophysiological and microdialysis studies, 8-OH-DPAT
(100–400 mg kg 1; s.c.), WAY100635 (N-[2-[4-(2-methoxy-
phenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)cyclohexanecarbox-
amide) (300 mg kg 1; s.c.) and were purchased from
Sigma-Aldrich (Saint-Quentin Fallavier, France).
Statistical analysis. For all experiments, statistical analysis
(StatView 5.0 Abacus Concepts, Berkeley, CA, USA) used
mean±s.e.m. Two-way analysis of variance with pre-
treatment (lenti-GFP vs lenti-BDNF) and treatment (vehicle
vs fluoxetine) factors was used followed by Fisher Protected
Least Significance Difference post hoc test. In the irradiation
experiments of lenti-BDNF mice, a two-way analysis of
variance with irradiation (sham vs X-ray) and treatment
(vehicle vs fluoxetine) factors was applied. Finally, hypother-
mic responses induced by 8-OH-DPAT were compared using
a three-way analysis of variance with repeated measures. In
specific cases, a Student’s t-test was used to compare two
groups of mice. Significant level was set at Po0.05.
The detail of the statistical analysis for each figure is
depicted in Supplementary Table S1.
Results
Validation of BDNF overexpression in the hippocampus
of adult mice. The ability of the BDNF-engineered lentiviral
vector to induce a detectable production of BDNF in the
hippocampus was determined using ELISA. A significantly
higher concentration of BDNF was observed in lenti-BDNF
mice compared with control lenti-GFP mice treated with
vehicle (Po0.001; Figure 1a). The administration of fluox-
etine significantly increased the concentration of BDNF in the
control lenti-GFP (Po0.01) but not in the lenti-BDNF mice
(P40.05; Figure 1a).
We next examined whether the BDNF-engineered lentiviral
vector increased the levels of activated (phosphorylated) ERK
and Akt in the rat hippocampus as an indirect marker of BDNF
secretion. A significant activation of both ERK and Akt was
detected in lenti-BDNF mice compared with control lenti-GFP
mice (Po0.001 and Po0.001, respectively; Figures 1b–d).
When treated with fluoxetine, the activation of both kinases
was significantly increased in lenti-GFP (Po0.01 and
Po0.05, respectively) but not in lenti-BDNF mice (P40.05
and P40.05, respectively).
Validation of glial cell transduction with GFP and
BDNF. The microinjection of lentiviral particles into the
hippocampus resulted in diffuse GFP expression. We
showed that GFP fluorescence obtained with this mokola-
pseudotyped lentiviral vector was localized to the subgra-
nular layer and hilus of the DG (Figures 1e and f), while no
expression was detected outside the hippocampus. Trans-
duced proteins were selectively expressed in astrocytes as
demonstrated by overlapping of GFP and GFAP immunos-
taining, whereas no GFP expression was detected in
neurons located in the granular layer (Figure 1f;
Supplementary Figure S2).
Behavioral response in lenti-BDNF adult mice
administered the vehicle or fluoxetine. Given the ability
of lentiviral vector to promote the production and release of
BDNF from astrocytes, we therefore assessed the behavioral
consequences of such manipulation in a battery of
sensitive tests to the chronic administration of fluoxetine
through neurogenesis-independent (EPM, TST and ST) and
neurogenesis-dependent (NSF) mechanism of action.5
In the EPM, the time spent in the open arms was unaltered
in lenti-BDNF mice compared with the control lenti-GFP mice
treated with vehicle (P40.05). Nevertheless, in response to
fluoxetine, a significant increase was observed in the lenti-
BDNF mice (Po0.01; Figure 2a) but not in lenti-GFP mice
(P40.05; Figure 2a) compared with their respective control
groups treated with vehicle. The total entries in the open arms
(Figure 2b) did not differ between the groups.
With respect to behavioral paradigms developed to
characterize antidepressant-like responses, in the TST our
results showed that the duration of immobility was not altered
in the control lenti-BDNF mice compared with the control
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lenti-GFP mice (P40.05; Figure 2c). However, fluoxetine
significantly decreased this parameter in both the lenti-GFP
mice (Po0.01) and the lenti-BDNF mice (Po0.001). This
antidepressant-like response to fluoxetine did not differ the
lenti-GFP and the lenti-BDNF groups (P40.05; Figure 2c).
Similarly, in the ST fluoxetine increased grooming behaviors
in both lenti-GFP (Po0.001) and lenti-BDNF mice (Po0.05)
compared with their respective control groups administered
the vehicle, while no differences between the lenti-GFP and
lenti-BDNF groups were detected (P40.05; Figure 2d).
In a last series of experiments, in the same animals, we
assessed the impact of BDNF overexpression in hippocampal
Figure 1 In vivo validaton of lentiviral vector on brain-derived neurotrophic factor (BDNF) overexpression/signaling and cellular tropism in the adult mouse hippocampus.
Mice were microinjected with either lentiviral vector-expressing green fluorescent protein (GFP) alone (Lenti-GFP) or lentiviral vector-expressing the human BDNF gene (Lenti-
BDNF) within the hippocampus. (a) In vivo measurements of BDNF concentration in the hippocampus of adult Lenti-GFP or Lenti-BDNF mice administered either with vehicle
(VEH; p.o.) or with fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks. Values are mean±s.e.m. of BDNF concentration (pg mg 1) (n¼ 3–8 per group). (b, c)
Phosphorylation of extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) in the hippocampus of adult mice microinjected with Lenti-GFP or Lenti-BDNF
administered either with vehicle (VEH; p.o.) or with fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks. Values are mean±s.e.m. of phospho-ERK or phospho Akt/total
ERK or total Akt (arbitrary unitary, a.u.) (n¼ 3–8 per group). *Po0.05, **Po0.01, ***Po0.001: significantly different from lenti-GFP mice administered with vehicle for 4
weeks. NS, not significant. (d) Western blot showing the phosphorylation of ERK and Akt in each experimental group. (e, f) Confocal micrographs ( 20 and  120) of a
representative transduced dentate gyrus (DG) showing the immunostaining for GFP- (green; up left panel), GFAP- (dark blue; down left panel) and NeuN-positive cells (red, up
right panel). Merged is depicted on the down right panel. The white arrows indicate transduced astrocytes.
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astrocytes in theNSF.We showed that the latency to feedwas
significantly decreased in the lenti-BDNFmice compared with
the control lenti-GFPmice (Po0.01; Figure 2e).When treated
with fluoxetine, the latency to feed was significantly decreased
in lenti-GFP (Po0.05), but not in lenti-BDNF mice compared
with their respective control groups (P40.05). At the end of
the test, the mice were immediately transferred to their home
cages, where food consumption wasmeasured for 5min. This
parameter used as a relative control for animal hunger and
body weight did not differ between groups (Figure 2f;
Supplementary Figure S3A).
Hippocampal neurogenesis in lenti-BDNF adult mice
administered the vehicle or fluoxetine. To further inves-
tigate the cellular mechanisms underlying the behavioral
effects of BDNF, we evaluated the impact of BDNF
overexpression in hippocampal astrocytes on adult hippo-
campal neurogenesis, which has been proposed as relevant
Figure 2 Anxiolytic-/antidepressant-like activity of fluoxetine in adult mice displaying an overexpression of brain-derived neurotrophic factor (BDNF) in hippocampal
astrocytes. (a, b) Anxiolytic-like effects of BDNF overexpression in hippocampal astrocytes of adult mice administered with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1
per day; p.o.) for 4 weeks in the elevated plus maze (EPM) test. Anxiety is measured as mean±s.e.m. of time spent in the open arms in seconds (a). Locomotor activity is
measured as mean±s.e.m. of number of entries in the open arms (b). (c, d) Antidepressant-like effects of BDNF overexpression in hippocampal astrocytes of adult mice
administered with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks evaluated in the tail suspension test (TST) (c) and splash test (d). Depression is
measured as mean±s.e.m. of the immobility time or grooming duration in seconds. (e, f) Anxiolytic-/antidepressant-like effects of BDNF overexpression in adult hippocampal
astrocytes in mice administered with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks evaluated in the novelty suppressed feeding (NSF) test. (e)
Mean±s.e.m. of latency to feed in seconds. (f) Mean±s.e.m. of food consumption (in mg g 1 of mice). In all tests: n¼ 10–20 per group. *Po0.05, **Po0.01, ***Po0.001:
significantly different from lenti-GFP (green fluorescent protein) mice administered with vehicle for 4 weeks. #Po0.05, ##Po0.01 and ###Po0.001: significantly different from
lenti-BDNF mice administered with vehicle. NS, not significant.
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for antidepressant action.1,5 The BDNF overexpression in
hippocampal astrocytes induced a significant proliferation of
progenitor cells as shown by an increase in the number of
Ki67-positive cells in the lenti-BDNF mice compared with the
control lenti-GFP mice (Po0.01; Figure 3a). Fluoxetine also
significantly increased this proliferation in lenti-GFP
(Po0.05), but not in lenti-BDNF mice (P40.05; Figure 3a)
compared with their respective control groups treated with
vehicle. A similar profile was observed for cell survival
(Figure 3b) and the maturation of young neurons, particularly
the number of DCX-positive cells with tertiary dendrites and
the maturation index (Figures 3d–f).
We also examined the relative ‘maturity’ of BrdUþNeuNþ
cells according to whether they express DCX. The number of
mature BrdUþ granule cells (BrdUþNeuNþDCX ) corre-
sponding to young neurons increased in response to
fluoxetine in the control lenti-GFP (Po0.05) and lenti-BDNF
mice, although the increase was not statistically significant in
the latter group (Po0.1). These results indicate that the
chronic fluoxetine administration similarly changed the fate
determination of early progenitors in lenti-GFP and lenti-
BDNF mice (Figure 3g).
In an attempt to correlate the anxiolytic-/antidepressant-like
effect of BDNF overexpression in hippocampal astrocytes in
the NSF with neurogenesis, we showed in lenti-BDNF mice
(treated with vehicle or fluoxetine) that the lower the latency to
feed, the higher the number of DCXþ cells with tertiary
dendrites. Although results did not reach statistical signifi-
cance (Po0.1 with an R2¼ 0.29; Figure 3h), they strongly
suggested a neurogenesis-dependent effect of BDNF over-
expression in the NSF. In marked contrast, the results
obtained from the EPM and the TST tests in lenti-BDNF mice
did not support this correlation (P¼ 0.8 in both tests
with R2¼ 0.01 and R2¼ 0.01, respectively; Supplementary
Figure S4).
Behavioral response in lenti-BDNF adult mice adminis-
tered the vehicle or fluoxetine after the disruption of
neurogenesis. To confirm the possibility that BDNF over-
expression in hippocampal astrocytes produced anxiolytic-/
antidepressant-like effects through neurogenesis-dependent
and neurogenesis-independent mechanisms, we examined
whether the ablation of neurogenesis through X-irradiation,
which does not affect glial cells density or hippocampal
morphology,1,26 blocked or attenuated the behavioral
responses observed in lenti-BDNF mice in a new batch of
animals (Figure 4; Supplementary Figure S5).
In the EPM, the application of X-irradiationmice did not alter
the effect of fluoxetine relative to sham mice (Po0.05). In
addition, the increase in time spent in open arms induced by
fluoxetine treatment was not different between sham and
X-ray-treated lenti-BDNFmice (P40.05; Figure 4a). The total
entries in open arms (Figure 4b) did not differ between groups.
In the TST and ST, fluoxetine produced antidepressant-like
activities in both sham and X-ray-treated mice (Po0.01 and
Po0.05, respectively, in the TST and Po0.05 and Po0.05,
respectively, in the ST; Figures 4c and d). Taken together,
these results suggest that fluoxetine has a neurogenesis-
independent effect on these behavioral paradigms.
In NSF, the application of x-irradiation on lenti-BDNF mice
administered the vehicle lowered the anxiolytic-/antidepres-
sant-like response, as indicated by the tendency to increase
the latency to feed compared with sham mice (P¼ 0.1).
Similarly, in lenti-BDNF mice administered fluoxetine, x-ray
treatment prevented the decrease in the latency to feed
observed in the sham mice (Po0.01), confirming that the
behavioral effect of BDNF overexpression alone or in
combination with fluoxetine requires neurogenesis to produce
behavioral effects in this test (Figure 4e). Food consumption
and body weight did not differ between the groups (Figure 4f;
Supplementary Figure S3B).
Changes in presynaptic serotonergic neuronal activity
in lenti-BDNF mice treated with vehicle or fluoxetine
Extracellular levels of 5-HT in the hippocampus and DR. We
then investigated whether the overexpression of BDNF in
hippocampal astrocytes affected the local extracellular levels of
5-HT using in vivo intracerebral microdialysis. Figure 5a shows
that the extracellular 5-HT levels in the hippocampus were not
modified in the lenti-BDNF mice compared with the control
lenti-GFP mice. Fluoxetine enhanced hippocampal 5-HT
outflow in both lenti-GFP and lenti-BDNF mice administered
fluoxetine compared with their corresponding group adminis-
tered the vehicle (Po0.001 and Po0.001). Nevertheless, the
enhancement of 5-HT outflow was significantly lower in the
hippocampus of lenti-BDNF compared with lenti-GFP mice
(Po0.05). Similar neurochemical profile was observed at the
somatodendritic level, that is, in the DR (Figure 5b).
Neuronal activity of DR 5-HT neurons. Next, we determined
whether changes in the extracellular levels of 5-HT resulted
from modifications of the firing rate of DR 5-HT neurons. It
has been shown previously that sub-chronic administration of
SSRIs decreases the DR 5-HT firing rate, and a gradual
Figure 3 Neurogenesis in response to fluoxetine in adult mice displaying an overexpression of brain-derived neurotrophic factor (BDNF) in hippocampal astrocytes.
(a) Ki-67 labeling to examine the effects of BDNF overexpression in hippocampal astrocytes of adult mice administered with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1
per day; p.o.) for 4 weeks on cell proliferation. Values are mean±s.e.m. of Ki67-positive cell counts (n¼ 5–6 per group). (b) BrdU (150 mg kg 1) was given twice a day for 3
days before drug treatment to examine the effects of BDNF overexpression in hippocampal astrocytes of adult mice administered with vehicle (VEH; p.o.) or fluoxetine (FLX,
18 mg kg 1 per day; p.o.) for 4 weeks on cell survival. Values are mean±s.e.m. of BrdU-positive cell counts (n¼ 5–6 per group). (c–f) Effects of BDNF overexpression in
hippocampal astrocytes of adult mice administered with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks. (c) Histological slices of the dentate
gyrus showing doublecortin (DCX) immunostaining in each experimental group ( 10) with 3D drawing of representative DCX-positive cells with dendritic complexity ( 40).
Total DCX-positive cells (d), DCX-positive cells with tertiary dendrites (e) as an index of young neurons maturation and maturation index (f) (n¼ 8–10 per group).
(g) Proportion of BrdUþNeuNþ cells that are DCXþ or DCX (percentage of BrdU cells) as an index of maturity. (h) Correlation between behavioral response in the NSF
and the number of DCX-positive cells with tertiary dendrites. Each point represents a lenti-BDNF mouse selected on the basis of its participation of both behavioral and
immunohistochemical studies. *Po0.05, **Po0.01, ***Po0.001: significantly different from lenti-green fluorescent protein (GFP) mice administered with vehicle. NS, not
significant.
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recovery to baseline is observed after prolonged administra-
tion.27 In the present study, the mean firing activity of
DR 5-HT neurons was similar between lenti-GFP mice
administered the vehicle and lenti-GFP mice administered
fluoxetine (1.4±0.1 vs 1.2±0.1Hz; P40.05, respectively;
Figures 5c and d). In contrast, in lenti-BDNF mice
administered fluoxetine, the firing rate of DR 5-HT neurons
was significantly lower than that obtained in lenti-BDNF mice
administered the vehicle (0.9±0.1 vs 1.5±0.09Hz;
Po0.001). Thus, in lenti-BDNF mice, DR 5-HT neurons did
not return to baseline as rapidly as lenti-GFP mice in
response to fluoxetine treatment.
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Functional status of presynaptic 5-HT1A autoreceptor in the
DR. To address the possibility that the decreased 5-HT
neurotransmission in lenti-BDNF mice administered fluoxe-
tine was associated with a reduced desensitization of the
inhibitory 5-HT1A autoreceptor, we examined the ability of the
5-HT1A receptor agonist 8-OH-DPAT to decrease the firing
rate of DR 5-HT neurons (Figures 5f and g). A marked
inhibition of DR 5-HT neuronal activity was observed in the
Figure 4 Effect of X-ray on fluoxetine response in adult mice with an overexpression of brain-derived neurotrophic factor (BDNF) in hippocampal astrocytes. (a, b)
Anxiolytic-like effects of BDNF overexpression in hippocampal astrocytes of adult mice administered with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4
weeks in the elevated plus maze (EPM) test. Anxiety is measured as mean±s.e.m. of time spent in the open arms in seconds (a). Locomotor activity is measured as
mean±s.e.m. of number of entries in the open arms (b). (c, d) Antidepressant-like effects of BDNF overexpression in hippocampal astrocytes of adult mice administered with
vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks evaluated in the tail suspension test (TST) (c) and splash test (d). Depression is measured as
mean±s.e.m. of the immobility time or grooming duration in seconds. (e, f) Anxiolytic-/antidepressant-like effects of BDNF overexpression in adult hippocampal astrocytes in
mice administered with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks evaluated in the novelty suppressed feeding (NSF) test.
(e) Mean±s.e.m. of latency to feed in seconds. (f) Mean±s.e.m. of food consumption (in mg g 1 of mice). In all tests: n¼ 10–15 per group. *Po0.05, **Po0.01:
significantly different from sham lenti-BDNF mice administered with vehicle. #Po0.05: significantly different from X-ray lenti-BDNF mice administered with vehicle. wwPo0.01:
significantly different from lenti-GFP (green fluorescent protein) mice administered with fluoxetine.
In vivo upregulation of BDNF in astrocytes by SSRIs
G Quesseveur et al
8
Translational Psychiatry
control lenti-GFP and lenti-BDNF mice administered the
vehicle. Consistent with a functional desensitization of the
5-HT1A autoreceptor, the ability of 8-OH-DPAT to suppress
5-HT neuronal firing activity was attenuated in lenti-GFP and
lenti-BDNF mice administered fluoxetine compared with their
respective control group (Po0.001 and Po0.001, respec-
tively; Figures 5f and g). However, in fluoxetine-administered
mice, the ability of 8-0H-DPAT to suppress DR 5-HT
neuronal activity was lower in lenti-BDNF than in lenti-GFP
mice (Po0.001).
To further explore the functional status of the 5-HT1A
autoreceptor, we evaluated the ability of 8-OH-DPAT to
decrease body temperature.28 In the present study, the
control lenti-GFP and lenti-BDNF mice administered the
vehicle displayed a robust hypothermic response to 8-OH-
DPAT. The prolonged administration of fluoxetine attenuated
this response in both lenti-GFP and lenti-BDNF mice
(Figure 5g). However, after fluoxetine treatment, the attenua-
tion of 8-OH-DPAT-induced hypothermia was less pro-
nounced in the lenti-BDNF mice than in the lenti-GFP mice
(Figure 5g).
Discussion
Adaptations induced through the use of chronic antidepres-
sants, most notably in the hippocampus, are related to the
upregulation of neurotrophic factors, such as BDNF,7 which
enhances adult neurogenesis.29 This phenomenon is
believed to be involved in the therapeutic activity of SSRIs.1
As such, developing pharmacological or genetic strategies
that stimulate the production and/or release of BDNF
represents promising approaches for the treatment of
psychiatric disorders. In physiological conditions, neurons
are the primary source of BDNF in the brain whereas
astrocytes have a role in the storage and secretion of this
neurotrophic substance.30 Growing evidence suggests how-
ever that this cell type may also synthesize BDNF at
functionally relevant levels under certain conditions such as
neuronal lesion17 or inflammation-like conditions.31 Interest-
ingly, it was recently proposed that astrocytes synthesize
BDNF in vitro in response to SSRIs20,32 and 5-HT/norepi-
nephrine or 5-HT/norepinephrine/dopamine reuptake inhibi-
tors.32 Such an event might have a significant role in the
therapeutic activity of these classes of antidepressant drugs.
The present study used a novel and efficient BDNF-gene
transfer strategy to shift the tropism of lentiviral vectors toward
astrocytes to determine whether these cells may be activated
by SSRIs to promote the in vivo synthesis/release of BDNF.
To our knowledge, although transgenic mice have been
engineered to overexpress BDNF into astrocytes,31 this
strategy is unique, notably due to the detargeting method
using micro ribonucleic acid to eliminate residual expression
of BDNF in neurons.21
In the hippocampus of mice injected with the Mokola vector,
a high density of astrocytes was transfected. As expected, the
intrahippocampal injection of the lentiviral vector significantly
increased local BDNF levels and related signaling as shown
by the stimulation of Erk and Akt phosphorylation. These data
seemingly confirm that BDNF was overexpressed and
secreted, even in the absence of fluoxetine treatment.
Similarly, when fluoxetine was administered for 28 days in
control lenti-GFP-transfected mice, a significant increase in
BDNF levels and kinases activation was observed. These
data are in agreement with the observation that the application
of fluoxetine or paroxetine upregulates BDNF mRNA and
protein levels in cultured cortical astrocytes or glioblastoma-
astrocytoma cells.20,33 They also suggest that SSRIs trigger a
signal stimulating astrocytes, which in turn elicits the in vivo
upregulation of BDNF in these cells. Given that the combina-
tion of fluoxetine with lenti-BDNF did not induce more
pronounced effects on BDNF levels and kinases activation
than those measured with either treatment alone, it can be
assumed that SSRIs and astrocytic BDNF acted through a
similar downstream mechanism. Alternatively, it is possible
that BDNF overexpression masked fluoxetine-induced neu-
ronal BDNF expression. However, the strong tendency of
fluoxetine to potentiate lenti-BDNF-induced increase in
hippocampal BDNF levels, Erk and Akt phosphorylation is
not in favor of the latter hypothesis.
Because the Mokola lenti-vector efficiently stimulated
hippocampal BDNF signaling, we examined whether these
molecular changes, induced through lenti-BDNF alone or in
combination with fluoxetine, modified the anxiolytic-/antide-
pressant-like responses of mice in various paradigms. One of
the most remarkable results obtained herein was the fact that
the overexpression of BDNF alone in hippocampal astrocytes
produced anxiolytic-/antidepressant-like activity in mice sub-
mitted to the NSF in relation to the stimulation of the adult
neurogenesis in the hippocampus. These data are in
agreement with previous findings showing that the fluoxe-
tine-induced anxiolytic-/antidepressant-like activity in the NSF
requires hippocampal neurogenesis.1,5 The good correlation
between the behavioral response in this paradigm and the
number of neurons with tertiary dendrites in lenti-BDNF mice
along with the fact that the ablation of hippocampal
neurogenesis compromised the behavioral effects of BDNF
overexpression, strengthened the hypothesis that hippocam-
pal astrocytic BDNF produces anxiolytic-/antidepressant-like
effects in a neurogenesis-dependent manner. Importantly,
several studies have reported a positive association between
the activation of BDNF/tropomyosin-related kinase B (TrkB)
signaling pathways, the upregulation of hippocampal neuro-
genesis and antidepressant-like activity of SSRIs8,34–36 but
the neuronal and/or astrocytic source of this factor had yet to
be determined. Because the antidepressant response might
have involved an excitatory action on the density of glial
cells,13,37 we also investigated whether BDNF overexpression
in hippocampal astrocytes alone or in combination with
fluoxetine modified the density of local GFAPþ cells. Our
results indicate that this parameter did not differ between
groups (Supplementary Figure S6), thus ruling out the
possibility that the secreted BDNF acted on astrocytes
themselves (autocrine mechanism) to generate newborn
neurons. This is in contrast with a recent study showing that
hippocampal BDNF infusion partially rescues the local
decreased GFAP expression in rats submitted to chronic mild
stress.38 Such a discrepancy may be due to the use of non-
stressed mice in the present study. Conversely, our results
strongly suggest a paracrine-like mechanism where hippo-
campal astrocytes constitute a microenvironment stimulating
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the synthesis and release of BDNF responsible for the
neurogenesis and anxiolytic-/antidepressant-like effect in
the NSF.
Some behavioral effects of fluoxetine do not require
neurogenesis, particularly in the EPM, TST and ST.5 There-
fore, we assessed the impact of BDNF overexpression in
In vivo upregulation of BDNF in astrocytes by SSRIs
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hippocampal astrocytes in these paradigms. As expected,
fluoxetine displayed a robust antidepressant-like activity in the
TST and ST. However, BDNF overexpression within astro-
cytes had no effects in these paradigms. This result can be
somewhat puzzling given that BDNF infusion in the hippo-
campus has been previously reported to improve behavioral
parameters such as despair.39,40 Several reasons may be
advanced to explain these differences such as the strain of
mice tested (129sV vs Swiss) or the part of the hippocampus
where BDNF or lenti-BDNF virus was injected (dorsal vs
ventral). Alternatively, it is possible that chronic overexpres-
sion of BDNF produced TrkB receptor desensitization,
whereas acute injection failed to do so. In the EPM, the
overexpression of BDNF did not produce anxiolytic-like
behavior. There is, however, accumulating evidence that
hippocampal BDNF has a role in anxiety. For example, mice
exhibiting decreased BDNF secretion or possessing a
truncated isoform of its preferential TrkB receptor, most
notably in newborn neurons,41 displayed an increased level of
anxiety,42,43 suggesting that the facilitation of BDNF/TrkB
signaling is required for anxiolysis. Although the present study
did not report an anxiolytic-like effect of BDNF overexpression
alone in hippocampal astrocytes, an anxiolytic-like activity of
fluoxetine was unveiled specifically in the group of BDNF-
transfected mice. These results are consistent with previous
findings showing that SSRIs produce anxiolysis after the
intrahippocampal injection of BDNF.39 They are also in
agreement with initial data reporting that fluoxetine was
unable to reverse increased anxiety-related behaviors in
BDNFþ / mice.42 Therefore, it appears that the overexpres-
sion of BDNF in hippocampal astrocytes favored the
anxiolytic-like activity of SSRI and this property did not require
neurogenesis because it was insensitive to X-irradiation. It is
noteworthy that the neurochemical and behavioral effects
observed in the present study might have resulted from viral
infection that has been shown previously to cause reactive
astrocytosis and neuroinflammation.44,45 However, it seems
unlikely that lenti-GFP alone increased BDNF signaling since
the value of BDNF levels obtained in the present study was
quite similar to that previously published by our group in
control mice.46 Moreover, we demonstrated that the lenti-GFP
alone was devoid of behavioral activity (Supplementary
Figure S7) thereby excluding the possibility of glial generation
of inflammatory molecules that would have modified beha-
vioral parameters.
To determine a putative mechanism by which BDNF
overexpression in hippocampal astrocytes regulated the
anxiolytic-like activities of fluoxetine in the EPM, we directed
our research on the regulation of the serotonergic system. The
overexpression of BDNF in hippocampal astrocytes did not
modify extracellular 5-HT concentrations in the hippocampus
or DR. However, consistent with previous findings,47 an
increase in extracellular 5-HT concentrations was detected in
response to the chronic administration of fluoxetine in both
lenti-GFP and lenti-BDNF mice. This neurochemical effect
was, however, less pronounced in the latter group of mice,
suggesting that the release of BDNF from hippocampal
astrocytes constituted a negative signal on 5-HT neurons.
These results were confirmed from the observation that in
lenti-BDNF mice, a challenge of fluoxetine significantly
increased hippocampal extracellular levels of 5-HT but this
neurochemical response was significantly lower than in lenti-
GFP mice (Supplementary Figure S8).
Because the ability of SSRIs to enhance 5-HT release is
strongly dependent on the firing rate of DR 5-HT neurons,48
we determined how neurochemical changes were reflected at
the electrophysiological level. No changes in the basal firing
rate of DR 5-HT neurons were detected in lenti-BDNF mice
administered the vehicle. Conversely, in response to fluox-
etine treatment, the firing rate was lower in lenti-BDNF mice
than in lenti-GFP mice, and this was reminiscent of the
neurochemical data. The acute or sub-chronic administration
of SSRIs typically reduces the neuronal activity of DR 5-HT
neuronal activity in rodents;49 therefore, the electrophysiolo-
gical response reported herein after 28 days of treatment
could be interpreted as a complete recovery to the basal firing
rate in lenti-GFP mice. Importantly, when fluoxetine was
administered in lenti-BDNF-transfected mice, this recovery of
firing seemed partial and might explain the reduced increase
in hippocampal and DR extracellular 5-HT levels. It is well
known that SSRI-induced progressive return to basal DR
5-HT firing rate results from progressive 5-HT1A autoreceptor
functional desensitization.50 Hence, we explored the func-
tional status of this 5-HT1A autoreceptor in lenti-GFP and
lenti-BDNF mice administered fluoxetine. Using two distinct
methods, we demonstrated that the degree of 5-HT1A
Figure 5 Effects of brain-derived neurotrophic factor (BDNF) overexpression in hippocampal astrocytes of adult mice administered with vehicle or fluoxetine on
serotonergic neuronal activity. (a, b) Extracellular levels of serotonin (5-HT) in the hippocampus and dorsal raphe (DR). Values are expressed as mean±s.e.m. of 5-HT levels
in the hippocampus (fmol per 20ml) (a) or in the DR (fmol per 10ml) (b) of lenti-GFP (green fluorescent protein) and lenti-BDNF mice administered vehicle (VEH; p.o.) or
fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks (n¼ 5–10 mice per group). (c, d) Electrophysiological activity of DR 5-HT neurons. (c) Scattergram depicting the firing
frequency of all spontaneously active 5-HT neurons encountered during systematic electrode descents through the DR of lenti-GFP and lenti-BDNF mice administered with
vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks (n¼ 4–5 mice per group). Lenti-GFP vehicle (39 cells recorded), Lenti-GFP fluoxetine (50 cells
recorded), lenti-BDNF vehicle (81 cells recorded) and lenti-BDNF fluoxetine (52 cells recorded). (d) Values are mean±s.e.m. of firing rate of DR 5-HT neurons in lenti-GFP
and lenti-BDNF mice administered with vehicle or fluoxetine. (e–g) Functional activity of 5-HT1A autoreceptor in the DR. (e) Representative integrated firing rate histograms
illustrating the effect of 8-OH-DPAT administrations in each group of mice. Note that at the end of each recording, the inhibitory effect of the 5-HT1A receptor agonist 8-OH-
DPAT is reversed by the 5-HT1A antagonist WAY100635 (300mg kg
 1; subcutaneous (s.c.)). (f) Values are mean±s.e.m. of the percentage of decrease in DR 5-HT firing
rate induced by the first dose of 8-OH-DPAT (100mg kg 1; s.c.). (g) Hypothermic effects of 8-OH-DPAT (100mg kg 1; s.c.) in lenti-GFP and lenti-BDNF mice administered
with vehicle (VEH; p.o.) or fluoxetine (FLX, 18 mg kg 1 per day; p.o.) for 4 weeks. Values are mean±s.e.m. for each time point of body temperature change from baseline
(1C). Baselines are calculated from the average from three temperature measures before 8-OH-DPAT administrations, each measure being performed with a 10-min interval
(n¼ 10–15 per group). **Po0.01 and ***Po0.001: significantly different from lenti-GFP mice administered with vehicle for 4 weeks. ##Po0.01 and ###Po0.001:
significantly different from lenti-BDNF mice administered with vehicle. wPo0.05, wwPo0.01 and wwwPo0.001: significantly different from lenti-GFP mice administered with
fluoxetine.
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autoreceptor desensitization induced through fluoxetine
treatment was blunted in lenti-BDNF mice; thus, this receptor
was able to maintain a significant inhibitory influence on 5-HT
neurons. These findings might seem puzzling because the
overexpression of BDNF was restricted to the hippocampus
(Supplementary Figure S1), while the electrophysiological
and hypothermic responses to 8-OH-DPAT are distally
regulated by the DR.28,47 However, given the presence of
the TrkB receptor on 5-HT neurons in rodents,39,51 an axonal
retrograde transport of BDNF from hippocampal 5-HT
terminals to their cell bodies within the DR is conceivable,
as previously shown following the local infusion of BDNF in
this brain region52 and in the rat occipital or entorhinal
cortex.53 In addition, because in vitro and in vivo evidence
demonstrates that BDNF modulates the 5-HT system,
particularly through the induction of the serotonergic pheno-
type,54,55 metabolism56,57 and axonal sprouting in the adult
brain,58,59 we postulate that the overexpression of BDNF in
hippocampal astrocytesmight have resulted in the remodeling
and growth of 5-HT dendrites in the DR, thereby increasing
the density of the inhibitory 5-HT1A autoreceptor in response
to fluoxetine. Such a mechanism might have participate to
maintain an inhibitory feedback induced on the 5-HT system
leading to an attenuation of extracellular 5-HT levels, which is
supposed to favor anxiolytic-like response. This hypothesis is
of particular interest since a recent study has demonstrated
that mice displaying a high density of 5-HT1A autoreceptor
display an attenuated response to stress and a lower
extracellular levels of 5-HT in the hippocampus after
fluoxetine treatement.28 Moreover, several pieces of evidence
indicate that increased 5-HT tone can increase anxiety
through activation of specific post-synaptic 5-HT receptors
(for example, the 5HT1A, 5-HT2A/C or 5-HT3 subtypes)
whereas genetic or pharmacological conditions that reduce
5-HT release would be a favorable condition for anxiolysis.60
Conclusion
The present data highlight a role for hippocampal astrocytes in
the synthesis of BDNF in vivo. Given that in physiological
conditions astrocytes express very low levels of BDNF, our
results suggest that the increase in extracellular 5-HT levels
induced by SSRIs might constitute a permissive signal to
stimulate such a synthesis. In addition, it clearly appears that
BDNF released from astrocytes acts on post-synaptic cells in
the hippocampus to stimulate neurogenesis and mediate
related anxiolytic-/antidepressant-like activities. Remarkably,
BDNF also influence the neuronal activity of presynaptic
neurons to prevent SSRI-induced increase in 5-HT tone. This
mechanism might be a prerequisite for the potentiation of the
anxiolytic-like effects of fluoxetine. Taken together, our results
illustrate the concept of the tripartite synapse61 in which
astrocytes may contribute in concert with neurons to increase
BDNF/5-HT relationship, and have an important role in
both neuronal functions and antidepressant-like activity
(Supplementary Figure S9). It is noteworthy that one limitation
of our study relies in the fact that some of the cells transfected,
albeit weak, looked like transiently amplifying progenitor cells.
We cannot rule out that the in vivo effects described herein
were not mediated, at least in part, by such a residual
overexpression of BDNF in non-glial cells. Our data require
therefore further confirmation by using a complementary
knockdown approach. If astrocytic BDNF effectively has a role
in the antidepressant action then a decreased SSRI activity
should be observed after its inactivation.
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